Dashboard
Manage Tickers

CNTA


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
12 Health Care Stocks Moving In Monday's A...
10/20/2025 21:08:49

guggenheim-reiterates-buy-on-centessa-pharmaceuticals-maintains-28-price-target
Guggenheim Reiterates Buy on Centessa Phar...
10/06/2025 13:14:31

Guggenheim analyst Debjit Chattopadhyay reiterates Centessa Pharmaceuticals (NASDAQ:CNTA) with a Buy and maintains $28 price...

3-biotech-stocks-showing-strength-with-big-spikes-in-momentum-scores
3 Biotech Stocks Showing Strength With Big...
09/12/2025 09:27:00

A handful of biotech stocks are showing renewed strength, with big spikes in their Benzinga Edge Ranking's Momentum scores.

wells-fargo-initiates-coverage-on-centessa-pharmaceuticals-with-overweight-rating-announces-price-target-of-31
Wells Fargo Initiates Coverage On Centessa...
09/03/2025 12:41:25

Wells Fargo analyst Benjamin Burnett initiates coverage on Centessa Pharmaceuticals (NASDAQ:CNTA) with a Overweight rating a...

chardan-capital-maintains-buy-on-centessa-pharmaceuticals-maintains-30-price-target
Chardan Capital Maintains Buy on Centessa ...
08/12/2025 20:27:59

Chardan Capital analyst Rudy Li maintains Centessa Pharmaceuticals (NASDAQ:CNTA) with a Buy and maintains $30 price target.

centessa-pharmaceuticals-q2-eps-038-misses-034-estimate
Centessa Pharmaceuticals Q2 EPS $(0.38) Mi...
08/12/2025 11:16:17

Centessa Pharmaceuticals (NASDAQ:CNTA) reported quarterly losses of $(0.38) per share which missed the analyst consensus estima...

chardan-capital-maintains-buy-on-centessa-pharmaceuticals-maintains-30-price-target
Chardan Capital Maintains Buy on Centessa ...
07/30/2025 22:05:43

Chardan Capital analyst Rudy Li maintains Centessa Pharmaceuticals (NASDAQ:CNTA) with a Buy and maintains $30 price target.

truist-securities-initiates-coverage-on-centessa-pharmaceuticals-with-buy-rating-announces-price-target-of-30
Truist Securities Initiates Coverage On Ce...
07/21/2025 11:54:35

Truist Securities analyst Danielle Brill initiates coverage on Centessa Pharmaceuticals (NASDAQ:CNTA) with a Buy rating and ...

centessa-pharmaceuticals-receives-fda-clearance-of-investigational-new-drug-application-for-orx142-with-clinical-data-in-acutely-sleep-deprived-healthy-volunteers-planned-for-this-year
Centessa Pharmaceuticals Receives FDA Clea...
06/16/2025 13:01:30

needham-initiates-coverage-on-centessa-pharmaceuticals-with-buy-rating-announces-price-target-of-35
Needham Initiates Coverage On Centessa Pha...
05/28/2025 10:25:12

Needham analyst Ami Fadia initiates coverage on Centessa Pharmaceuticals (NASDAQ:CNTA) with a Buy rating and announces Price...

centessa-pharmaceuticals-q1-eps-020-beats-037-estimate-sales-1500m
Centessa Pharmaceuticals Q1 EPS $(0.20) Be...
05/14/2025 11:04:14

Centessa Pharmaceuticals (NASDAQ:CNTA) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate...

this-centessa-pharmaceuticals-analyst-begins-coverage-on-a-bullish-note-here-are-top-2-initiations-for-thursday
This Centessa Pharmaceuticals Analyst Begi...
05/08/2025 14:42:35

chardan-capital-initiates-coverage-on-centessa-pharmaceuticals-with-buy-rating-announces-price-target-of-30
Chardan Capital Initiates Coverage On Cent...
05/08/2025 11:17:22

Chardan Capital analyst Rudy Li initiates coverage on Centessa Pharmaceuticals (NASDAQ:CNTA) with a Buy rating and announces...

piper-sandler-initiates-coverage-on-centessa-pharmaceuticals-with-overweight-rating-announces-price-target-of-38
Piper Sandler Initiates Coverage On Centes...
03/31/2025 10:05:53

Piper Sandler analyst Biren Amin initiates coverage on Centessa Pharmaceuticals (NASDAQ:CNTA) with a Overweight rating and a...

guggenheim-reiterates-buy-on-centessa-pharmaceuticals-maintains-28-price-target
Guggenheim Reiterates Buy on Centessa Phar...
03/26/2025 13:47:47

Guggenheim analyst Debjit Chattopadhyay reiterates Centessa Pharmaceuticals (NASDAQ:CNTA) with a Buy and maintains $28 price...

centessa-pharmaceuticals-q4-2024-gaap-eps-084-misses-040-estimate
Centessa Pharmaceuticals Q4 2024 GAAP EPS ...
03/24/2025 11:06:26

morgan-stanley-assumes-centessa-pharmaceuticals-at-overweight-maintains-price-target-of-27
Morgan Stanley Assumes Centessa Pharmaceut...
03/07/2025 17:14:20

Morgan Stanley analyst Jeffrey Hung assumes Centessa Pharmaceuticals (NASDAQ:CNTA) with a Overweight rating and maintains Pr...

centessa-pharmaceuticals-announces-poster-presentation-of-phase-1-clinical-data-for-orx750-a-novel-orexin-receptor-2-agonist-at-the-aan-2025-annual-meeting
Centessa Pharmaceuticals Announces Poster ...
03/06/2025 21:24:35

Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines...

aerovironment-posts-downbeat-results-joins-box-crowdstrike-and-other-big-stocks-moving-lower-in-wednesdays-pre-market-session
AeroVironment Posts Downbeat Results, Join...
03/05/2025 11:50:19

guggenheim-reiterates-buy-on-centessa-pharmaceuticalsto-buy
Guggenheim Reiterates Buy on Centessa Phar...
02/10/2025 14:11:25

Guggenheim analyst Debjit Chattopadhyay reiterates Centessa Pharmaceuticals (NASDAQ:CNTA) from Buy to Buy.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION